Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

KIDNEY CANCER

Substituting SABR for systemic therapy in oligometastatic renal cell carcinoma — buying time or time to change?

Nature Reviews Urology volume 19, pages 197–198 (2022)Cite this article

Subjects

In this prospective trial in oligometastatic renal cell carcinoma (RCC), the first of its kind, stereotactic ablative body radiotherapy was delivered successfully in lieu of systemic therapy. This strategy should be considered in selected patients with oligometastatic RCC.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Barney, J. D. & Churchill, E. J. Adenocarcinoma of the kidney with metastasis to the lung: cured by nephrectomy and lobectomy. J. Urol. 42, 269–276 (1939).

    Article  Google Scholar 

  2. Siva, S. et al. Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach. Nat. Rev. Urol. 14, 549–563 (2017).

    Article  Google Scholar 

  3. Deschavanne, P. J. & Fertil, B. A review of human cell radiosensitivity in vitro. Int. J. Radiat. Oncol. Biol. Phys. 34, 251–266 (1996).

    Article  CAS  Google Scholar 

  4. Zaorsky, N. G., Lehrer, E. J., Kothari, G., Louie, A. V. & Siva, S. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies. Eur. Urol. Oncol. 2, 515–523 (2019).

    Article  Google Scholar 

  5. Motzer, R. J. et al. Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 15, 804–834 (2017).

    Article  Google Scholar 

  6. Tang, C. et al. Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. Lancet Oncol. 22, 1732–1739 (2021).

    Article  Google Scholar 

  7. Rini, B. I. et al. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol. 17, 1317–1324 (2016).

    Article  Google Scholar 

  8. Cheung, P. et al. Stereotactic radiotherapy for oligoprogression in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor therapy: a phase 2 prospective multicenter study. Eur. Urol. 80, 693–700 (2021).

    Article  CAS  Google Scholar 

  9. Turgeon, G.-A., Weickhardt, A., Azad, A. A., Solomon, B. & Siva, S. Radiotherapy and immunotherapy: a synergistic effect in cancer care. Med. J. Aust. 210, 47–53 (2019).

    Article  Google Scholar 

  10. Siva, S. et al. Stereotactic radiotherapy and short-course pembrolizumab for oligometastatic renal cell carcinoma — the RAPPORT trial. Eur. Urol. https://doi.org/10.1016/j.eururo.2021.12.006 (2021).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

    Shankar Siva

  2. Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia

    Shankar Siva

  3. Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada

    Alexander V. Louie

Authors
  1. Shankar Siva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander V. Louie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shankar Siva.

Ethics declarations

Competing interests

S.S. has received honoraria from AstraZeneca for Speaker’s Bureau and Advisory board, and research grants from Varian Industries. A.V.L. has received honoraria from AstraZeneca for Speaker’s Bureau and Advisory board.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Siva, S., Louie, A.V. Substituting SABR for systemic therapy in oligometastatic renal cell carcinoma — buying time or time to change?. Nat Rev Urol 19, 197–198 (2022). https://doi.org/10.1038/s41585-021-00560-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-021-00560-3

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer